公开(公告)号：EP2585826A1

公开(公告)日：2013-05-01

申请号：EP11798515.0

申请日：2011-06-23

申请人： Astute Medical, Inc.

发明人： ANDERBERG, Joseph ,  GRAY, Jeff ,  MCPHERSON, Paul ,  NAKAMURA, Kevin ,  KAMPF, James, Patrick

IPC分类号： G01N33/48 ,  G01N33/53

CPC分类号： G01N33/6893 ,  G01N33/6854 ,  G01N33/6863 ,  G01N33/74 ,  G01N2333/4725 ,  G01N2333/4745 ,  G01N2333/495 ,  G01N2333/521 ,  G01N2333/5431 ,  G01N2333/7155 ,  G01N2333/96472 ,  G01N2333/96494 ,  G01N2800/347 ,  G01N2800/50 ,  G01N2800/56

摘要： The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of C-C Motif chemokine 24, and optinally Cancer antigen CA 15-3, C-C Motif chemokine 18, , Cathepsin D, C-X-C Motif chemokine 13, C-C motif chemokine 8, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, Interleukin-11, Matrix Metalloproteinase-8, Transforming growth factor alpha, IgG1, and IgG2 as diagnostic and prognostic biomarkers in renal injuries.

摘要翻译： 本发明涉及用于监测，诊断，预后和确定患有或怀疑患有肾损伤的受试者的治疗方案的方法和组合物。 具体而言，本发明涉及使用一种或多种配置为检测选自癌抗原CA 15-3，CC基元趋化因子18，CC基元趋化因子24，组织蛋白酶D，CXC基元趋化因子13 ，CC基序趋化因子8，白细胞介素-2受体α链，胰岛素样生长因子结合蛋白3，白细胞介素-11，基质金属蛋白酶-8，转化生长因子α，IgG1和IgG2作为诊断和预后生物标记物在肾损伤中的应用。

公开(公告)号：EP2899545A1

公开(公告)日：2015-07-29

申请号：EP15151607.7

申请日：2011-06-23

申请人： Astute Medical, Inc.

发明人： Anderberg, Joseph ,  Gray, Jeff ,  McPherson, Paul ,  Nakamura, Kevin ,  Kampf, James Patrick

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  G01N33/6854 ,  G01N33/6863 ,  G01N33/74 ,  G01N2333/4725 ,  G01N2333/4745 ,  G01N2333/495 ,  G01N2333/521 ,  G01N2333/5431 ,  G01N2333/7155 ,  G01N2333/96472 ,  G01N2333/96494 ,  G01N2800/347 ,  G01N2800/50 ,  G01N2800/56

摘要： The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of C-C Motif chemokine 24, and optinally Cancer antigen CA 15-3, C-C Motif chemokine 18, , Cathepsin D, C-X-C Motif chemokine 13, C-C motif chemokine 8, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, Interleukin-11, Matrix Metalloproteinase-8, Transforming growth factor alpha, IgG1, and IgG2 as diagnostic and prognostic biomarkers in renal injuries.

摘要翻译： 本发明涉及一种用于在患有或疑似患有肾损伤的受试者监测，诊断，预后和确定治疗方案的方法和组合物。 特别地，本发明涉及使用被配置一个或多个测定中，以检测选自CC趋化因子的基序24选择的肾损伤标记物，和optinally癌抗原CA 15-3，CC趋化因子基序18，组织蛋白酶D，CXC 基序趋化因子13，CC基序趋化因子8，白介素-2受体α链，胰岛素样生长因子结合蛋白3，白细胞介素-11，基质金属蛋白酶8，转化生长因子α，IgG1的，和IgG2如在诊断和预后标志物 肾损伤。

公开(公告)号：EP2899545B1

公开(公告)日：2018-08-22

申请号：EP15151607.7

申请日：2011-06-23

申请人： Astute Medical, Inc.

发明人： Anderberg, Joseph ,  Gray, Jeff ,  McPherson, Paul ,  Nakamura, Kevin ,  Kampf, James Patrick

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  G01N33/6854 ,  G01N33/6863 ,  G01N33/74 ,  G01N2333/4725 ,  G01N2333/4745 ,  G01N2333/495 ,  G01N2333/521 ,  G01N2333/5431 ,  G01N2333/7155 ,  G01N2333/96472 ,  G01N2333/96494 ,  G01N2800/347 ,  G01N2800/50 ,  G01N2800/56

摘要： The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of C-C Motif chemokine 24, and optinally Cancer antigen CA 15-3, C-C Motif chemokine 18, , Cathepsin D, C-X-C Motif chemokine 13, C-C motif chemokine 8, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, Interleukin-11, Matrix Metalloproteinase-8, Transforming growth factor alpha, IgG1, and IgG2 as diagnostic and prognostic biomarkers in renal injuries.

公开(公告)号：EP2585826A4

公开(公告)日：2013-12-04

申请号：EP11798515

申请日：2011-06-23

申请人： ASTUTE MEDICAL INC

发明人： ANDERBERG JOSEPH ,  GRAY JEFF ,  MCPHERSON PAUL ,  NAKAMURA KEVIN ,  KAMPF JAMES PATRICK

IPC分类号： G01N33/48 ,  G01N33/53 ,  G01N33/68

CPC分类号： G01N33/6893 ,  G01N33/6854 ,  G01N33/6863 ,  G01N33/74 ,  G01N2333/4725 ,  G01N2333/4745 ,  G01N2333/495 ,  G01N2333/521 ,  G01N2333/5431 ,  G01N2333/7155 ,  G01N2333/96472 ,  G01N2333/96494 ,  G01N2800/347 ,  G01N2800/50 ,  G01N2800/56

摘要： The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of C-C Motif chemokine 24, and optinally Cancer antigen CA 15-3, C-C Motif chemokine 18, , Cathepsin D, C-X-C Motif chemokine 13, C-C motif chemokine 8, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, Interleukin-11, Matrix Metalloproteinase-8, Transforming growth factor alpha, IgG1, and IgG2 as diagnostic and prognostic biomarkers in renal injuries.

摘要翻译： 本发明涉及用于监测，诊断，预后和确定患有或怀疑患有肾损伤的受试者的治疗方案的方法和组合物。 具体而言，本发明涉及使用一种或多种配置为检测选自癌抗原CA 15-3，CC基元趋化因子18，CC基元趋化因子24，组织蛋白酶D，CXC基元趋化因子13 ，CC基序趋化因子8，白细胞介素-2受体α链，胰岛素样生长因子结合蛋白3，白细胞介素-11，基质金属蛋白酶-8，转化生长因子α，IgG1和IgG2作为诊断和预后生物标记物在肾损伤中的应用。